Effect of spironolactone wash‐out on albuminuria after long‐term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow‐up of the PRIORITY study
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16037 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Victor Wasehuus und 13 weiteren Autor:innen. Beteiligte Einrichtung: Steno Diabetes Center Copenhagen, Herlev, Denmark. Hauptthemen laut MEDLINE: Spironolactone, Albuminuria, Diabetes Mellitus, Type 2, Diabetic Nephropathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Seventh Framework Programme.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
This study aimed to explore the effect of discontinuation of long‐term spironolactone treatment on markers of kidney function in individuals with type 2 diabetes (T2D) at high risk of kidney disease enrolled in the Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria (PRIORITY) study. Materials and Methods An observational study following the nested randomised part of the PRIORITY study was conducted. A total of 115 individuals with T2D and normoalbuminuria but high risk for progression based on urinary proteomics, randomised to daily spironolactone ( n = 50) or placebo ( n = 65) for a median of 2.5 years, were re‐examined approximately 6 weeks after the final visit in the PRIORITY study. Primary endpoint was relative change in geometric mean of urinary albumin‐creatinine ratio (UACR) between the final visit in PRIORITY (baseline) and follow‐up. Secondary endpoints were change in estimated glomerular filtration rate (eGFR), systolic blood pressure (SBP) and serum potassium.
Results
No change in UACR was observed in neither the spironolactone (geometric mean change: 17%; 95% CI −12, 55; p = 0.28) nor the placebo (5%; 95% CI −13, 26; p = 0.63) group at follow‐up. No difference in UACR between the groups was observed at follow‐up (relative difference in geometric mean: 11%, 95% CI −26, 67; p = 0.60). For eGFR and SBP, an increase after discontinuation of spironolactone was observed, as well as for SBP after placebo discontinuation. Potassium levels were lower after discontinuation of spironolactone, but higher after placebo discontinuation (all p < 0.05).
Conclusions
UACR did not change after discontinuation of long‐term treatment with spironolactone. However, an increase in eGFR was observed supporting a haemodynamic effect of spironolactone in the kidneys.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Steno Diabetes Center Copenhagen, Herlev, Denmark.
- Department of Medicine, Holbæk Hospital, Holbæk, Denmark.
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
- Mosaiques Diagnostics, Hannover, Germany.
- Orgenesis Inc, Germantown, Maryland, USA.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Victor Wasehuus, Viktor Rotbain Curovic, Nete Tofte, Morten Lindhardt, Gemma Currie, Christian Delles, Marie Frimodt-Møller, Harald Mischak, Tine Willum Hansen, Thomas Kümler, Frederik Persson, Peter Rossing
Förderung
- Seventh Framework Programme
Zitieren
APA
Wasehuus, V., Rotbain Curovic, V., Tofte, N., Lindhardt, M., Currie, G., Delles, C., Frimodt-Møller, M., Mischak, H., von der Leyen, H., Hansen, T. W., Kümler, T., Persson, F., Rossing, P., & PRIORITY Study group (2025). Effect of spironolactone wash‐out on albuminuria after long‐term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow‐up of the PRIORITY study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16037
Vancouver
Wasehuus V, Rotbain Curovic V, Tofte N, Lindhardt M, Currie G, Delles C, et al. Effect of spironolactone wash‐out on albuminuria after long‐term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow‐up of the PRIORITY study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16037
BibTeX
@article{Wasehuus2025,
author = {Wasehuus, Victor and Rotbain Curovic, Viktor and Tofte, Nete and Lindhardt, Morten and Currie, Gemma and Delles, Christian and Frimodt-Møller, Marie and Mischak, Harald and von der Leyen, Heiko and Hansen, Tine Willum and Kümler, Thomas and Persson, Frederik and Rossing, Peter and PRIORITY Study group, PRIORITY Study group},
title = {Effect of spironolactone wash‐out on albuminuria after long‐term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow‐up of the PRIORITY study},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16037}
}
EUVIMED